Madrigal Pharmaceuticals stock: New F4 study, late-2027 readout
Published on 11/17/2026 at 22:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMadrigal expands its MASH strategy
- Management presented a larger F4 outcomes study designed to incorporate new biomarker and risk-stratification insights.
- The ongoing MAESTRO-NASH OUTCOMES trial is now expected to report in late 2027.
- REZDIFFRA treatment exceeded 55,850 patients, according to the conference discussion.
Madrigal Pharmaceuticals presented a new, larger F4 outcomes study and narrowed the expected readout for its ongoing MAESTRO-NASH OUTCOMES trial to late 2027 at the Jefferies Global Healthcare Conference on Tuesday, November 17, 2026. A transcript published by Investing.com captured the management discussion.
Madrigal said the new study will use lessons from the current trial, open-label data and newer approaches to identify patients at higher risk of liver-related events. Management described the move as part of a strategy to build a leadership position across F2, F3 and compensated F4 cirrhosis rather than as a response to a weakness in the existing program.
Late-2027 trial timing
The ongoing MAESTRO-NASH OUTCOMES study includes 845 patients with compensated cirrhosis. Chief Medical Officer Dave Berman said the company had accumulated enough events to narrow the expected timing from a broader 2027 window to late 2027, while noting that the final timing depends on the pace of event accumulation.
The planned follow-on study is intended to apply more refined risk stratification, including the ANTICIPATE-NASH algorithm and emerging blood biomarkers. Madrigal said the design will place greater emphasis on patients with features associated with a higher likelihood of progression.
Commercial launch remains central
Management said more than 55,850 patients were receiving REZDIFFRA, the company's treatment for metabolic dysfunction-associated steatohepatitis. It also said quarterly additions were running at roughly 6,000 to 7,000 patients and that real-world safety monitoring had not identified signals inconsistent with the approved label.
Madrigal Pharmaceuticals stock traded at 383.45 euros on Lang & Schwarz at 10:07 p.m. Berlin time on Tuesday, November 17, 2026.
Madrigal Pharmaceuticals
- Company: Madrigal Pharmaceuticals, Inc.
- ISIN: US5588681057
- Ticker: MDGL
- Home exchange: Nasdaq
- Lang & Schwarz price: 383.45 euros at 10:07 p.m. Berlin time, November 17, 2026
The Nasdaq Composite provides the relevant market backdrop for Madrigal Pharmaceuticals stock: Current Nasdaq market reports.
